dc.contributor.author
Bafadhel, Mona
dc.contributor.author
Faner, Rosa
dc.contributor.author
Taillé, Camille
dc.contributor.author
Russell, Richard E. K.
dc.contributor.author
Welte, Tobias
dc.contributor.author
Barnes, Peter J.
dc.contributor.author
Agustí García-Navarro, Àlvar
dc.date.issued
2023-05-11T14:22:59Z
dc.date.issued
2023-05-11T14:22:59Z
dc.date.issued
2023-05-11T14:22:59Z
dc.identifier
https://hdl.handle.net/2445/197869
dc.description.abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms
dc.format
application/pdf
dc.relation
Reproducció del document publicat a: https://doi.org/10.1183/16000617.0099-2022
dc.relation
European Respiratory Review, 2022, vol. 31, p. 220099
dc.relation
https://doi.org/10.1183/16000617.0099-2022
dc.rights
cc-by (c) Bafadhel, Mona et al., 2022
dc.rights
https://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Biomedicina)
dc.subject
Corticosteroides
dc.subject
Adrenocortical hormones
dc.title
Inhaled corticosteroids for the treatment of COVID-19
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
